drugset / Trial / NCT00474526

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526

Phase 3 Completed 4545 enrolled Novartis Vaccines
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.

Timeline

Start
2007-03
Primary completion
2008-09
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ActHIB® (Haemophilus influenzae type b Conjugate Vaccine) Vaccine
Subject DTaP-IPV-HBV Vaccine
Subject Havrix® (Hepatitis A Vaccine, Inactivated) Vaccine
Subject Infanrix® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Vaccine
Subject Menveo Vaccine
Subject Prevnar 13 Vaccine
Subject ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine) Vaccine
Subject Rotavirus Vaccine Oral